Loading...
XNAS
ASBP
Market cap69mUSD
Jul 09, Last price  
6.07USD
1D
5.02%
1Q
-80.91%
IPO
-99.95%
Name

Aspire Biopharma Holdings Inc

Chart & Performance

D1W1MN
XNAS:ASBP chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
6k
00006,202
Net income
-24m
L+95.27%
-25,4753,340,0004,464,000-12,537,000-24,480,848
CFO
-5m
L+1,756.62%
-260-1,408,786-653,107-265,186-4,923,488

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
URL
IPO date
Feb 18, 2022
Employees
Domiciled in
PR
Incorporated in
US

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT